In Vitro: In vitro signaling experiments, LIT-001 free base is a nonbiased OT-R agonist on the two main signaling pathways of this receptor, with minor antagonist effect on V1a and agonist effect on V1b receptors, observed at high concentrations only.
In Vivo: LIT-001 free base (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD ).